New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity

Thrombosis Research

Volumn 83, Issue 3, 1996, Pages 217-228

  Doutremepuich, C ^a   Azougagh, Oualane F ^a   Doutremepuich, F ^a   Fareed, J ^b  

^a Lab d'Hematologie Pharmaceut   (France)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

antithrombotic activity; hemorrhagic activity; heparin derivatives

Indexed keywords

ENOXAPARIN; HEPARIN DERIVATIVE; PROTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; DRUG CONFORMATION; DRUG EFFICACY; DRUG MIXTURE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBIN TIME; THROMBOSIS;

EID: 0030220564     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00130-2     Document Type: Article

References (28)

1. ANDO, T, YAMASAKI, M and SUZUKI, K. Protamine : Isolation, Characterization Structure and Functions. Springer. Verlag New York pp 3-94, 1973.
2. ARONSON, M, FABIAN, I and BLEIBERG, I. Mecanism of heparin rebound and heparin-protamine interactions. In heparin new biochemical and medical aspects. I de whited. De Gruyter Berlin, 69-95, 1983.
3. ARTHUR U.K, ISBISTER J.P, ASPERY E.M. The heparin induced thrombosis-thrombocytopenia syndrome (HITTS): a review. Pathology. 16:1985;82-86.
4. AZOUGAGH OUALANE F, TOULEMONDE F, DOUTREMEPUICH F, DOUTREMEPUICH C. Effects of aprotinin on heparin activities and neutralization with protamine. Thromb. Res. 68:1992;185-193.
5. BARROWCLIFFE T.W, MERTON R.E, GRAY E, THOMAS D.P. Heparin and bleeding : A association with lipase release. Thromb. Haemost. 60:1988;434-436.
6. BERGQVIST D, HEDNER U, SJÖRIN E, HOLMER E. Anticoagulant effects of two types of low molecular weight heparin administred subcutaneously. Thromb. Res. 32:1983;381-391.
7. BIANCHINI P, OSIMA B, NADER H.B, DIETRICH C.P. Lack of correlation between in vitro and in vivo antithrombotic activity of heparin fractions and related compounds. Thromb. Res. 40:1985;597-607.
8. BROUTY-BOYE H, TOULEMONDE F, DOUTREMEPUICH F, MARSH N, GAFFNEY J.L. Heparin and a low molecular weight fraction enhance thrombolysis and by this pathway exert a protective effect against thrombosis. Thromb. Res. 30:1983;219-224.
9. BROZOVIC, M and BANGHAM, D.R. Standards for heparin in advances in experimental medecine an Biology vol 52. Bradwhaw Wessler Ed. Plenum Press. NY 1976.
10. CADE J.F, BUCHANAN M.R, BONEU B, CARTER C.J, CERSKUS A.L, HIRSH J. A comparaison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the methods of preparation. Thromb. Res. 35:1984;613-625.
11. CARDINAL D.C, FLOWER R.J. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J. Pharm. Meth. 3:1980;135-158.
12. CHARGAFF E, OLSON K.B. Studies on Chemistry of blood coagulation VI. Studies on the action of heparin and other anticoagulants. The influence of protamine on the anticoagulant effect in vivo. J. Biol. Chem. 122:1937;153-157.
13. DEJANA E, VILLA S, DE GAETANO G Bleeding time in rats : a comparison of different experimental conditions. Thromb. Res. 48:1982;108-111.
14. DINESS V, and OSTERGAARD, P.B. Neutralization of LMWH (LHN-1) and conventional by heparin sulfates in rats. Thromb. Haemost. 56, 318-22, 1986.
15. DOUTREMEPUICH C, BONINI F, DE SEZE O, TOULEMONDE F, BAYROU B. Neutralisation d'une fraction d'héparine de très faible masse moléculaire CY222 par la protamine Etude in vitro et in vivo. Thérapie. 41:1986;433-436.
16. DOUTREMEPUICH C, BONINI F, TOULEMONDE F, BERTRAND H, BAYROU B, QUILICHINI R In vivo neutralization of low molecular weight heparin fraction CY216 by protamine. Sem. Thromb. Hemost. 11:1985;316-318.
17. DOUTREMEPUICH C, GESTREAU H, MAURY M.O, QUILICHINI R, BOISSEAU M.R, TOULEMONDE F, VAIREL E. Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostatis. 13:1983;109-112.
18. HIRSH J. Heparin induced bleeding. Nouv. Rev. Franç. Hematol. 26:1984;261-266.
19. KELTON J.G, HIRSH J. Bleeding associated with antithrombotic therapy. Semin. Hematol. 17:1980;259-291.
20. KITANI T, NAGARAJAN S.C, SHANBERGE J.N. Effect of Protamine on heparin ATIII complexes. In vivo studies. Thromb. Res. 17:1980;367-374.
21. KITANI T, NAGARAJAN S.C, SHANBERGE J.N. Effect of Protamine on heparin ATIII complexes. In vivo studies. Thromb. Res. 17:1980;375-382.
22. LEVY S.W, JACQUES L.B. Apparence of heparin antithrombin active chains in vivo after injection of commercial heparin and anaphylaxis. Thromb. Res. 13:1978;429-441.
23. MASSONNET-CASTEL S, PELISSIER E, BARA L, TERRIER E, ABRY B, GUIBOURT P, SWANSON J, JAULMES B, CARPENTIER A, SAMAMA M. Partial reversal of low molecular weight Heparin (PK 10169) anti-Xa activity by protamine sulfate. In vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 16:1986;139-146.
24. RACANELLI A, FAREED J, WALENGA J, COYNE E. Biochemical and pharmacologic studies on the protamine interaction with heparin, its fractions and fragments. Sem Thromb Hemost. 11:1985;176-189.
25. RACANELLI A, HOPPENSTEADT D.A, FAREED J. In vitro protamine neutralization profiles of heparins differing in source and molecular weight. Sem Thromb. Hemost. 15:1989;386-389.
26. REYERS I, MUSSONI L, DONATI M.B, De GAETANO G. Thrombosis induced by ligature of inferior vena cava (rats). Thromb. Res. 18:1980;669-674.
27. ROSS R.L., WHITTLESEY G.C., SPLITTGERBER F.H., SALLEY S.O., KLEIN M.D. Rapid assays for heparin during extracorporeal circulation. Trans. Am. Soc; Artif. Inter. Organs. 13:1986;274-277.
28. THOMAS D.P, BARROWCLIFFE T.W, MERTON R.E, STOCKS J, DAWIES J, PEPPER D.S. In vivo release of anti Xa clotting activity by a heparin analogue. Thromb Res. 17:1980;831-840.